1. Home
  2. ALLO vs JOF Comparison

ALLO vs JOF Comparison

Compare ALLO & JOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • JOF
  • Stock Information
  • Founded
  • ALLO 2017
  • JOF 1990
  • Country
  • ALLO United States
  • JOF Japan
  • Employees
  • ALLO N/A
  • JOF N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • JOF Trusts Except Educational Religious and Charitable
  • Sector
  • ALLO Health Care
  • JOF Finance
  • Exchange
  • ALLO Nasdaq
  • JOF Nasdaq
  • Market Cap
  • ALLO 277.8M
  • JOF 267.8M
  • IPO Year
  • ALLO 2018
  • JOF N/A
  • Fundamental
  • Price
  • ALLO $1.21
  • JOF $9.75
  • Analyst Decision
  • ALLO Strong Buy
  • JOF
  • Analyst Count
  • ALLO 9
  • JOF 0
  • Target Price
  • ALLO $8.44
  • JOF N/A
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • JOF 43.9K
  • Earning Date
  • ALLO 08-06-2025
  • JOF 01-01-0001
  • Dividend Yield
  • ALLO N/A
  • JOF 3.33%
  • EPS Growth
  • ALLO N/A
  • JOF N/A
  • EPS
  • ALLO N/A
  • JOF N/A
  • Revenue
  • ALLO N/A
  • JOF N/A
  • Revenue This Year
  • ALLO N/A
  • JOF N/A
  • Revenue Next Year
  • ALLO $199.63
  • JOF N/A
  • P/E Ratio
  • ALLO N/A
  • JOF N/A
  • Revenue Growth
  • ALLO N/A
  • JOF N/A
  • 52 Week Low
  • ALLO $0.86
  • JOF $6.64
  • 52 Week High
  • ALLO $3.78
  • JOF $8.04
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 43.73
  • JOF 67.22
  • Support Level
  • ALLO $1.11
  • JOF $9.64
  • Resistance Level
  • ALLO $1.29
  • JOF $9.78
  • Average True Range (ATR)
  • ALLO 0.09
  • JOF 0.10
  • MACD
  • ALLO -0.01
  • JOF -0.00
  • Stochastic Oscillator
  • ALLO 25.81
  • JOF 102.33

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About JOF Japan Smaller Capitalization Fund Inc

Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.

Share on Social Networks: